Ocular surface squamous neoplasia (OSSN) represents a spectrum of diseases ranging from mild dysplasia to invasive squamous cell carcinoma. Ocular surface squamous neoplasia can be successfully managed with surgical excision or medical therapy. Interferon-α-2b (IFNα-2b) treatment recently has been established as a standard treatment option for OSSN, eliminating the need for surgical excision. However, approximately 15% of tumors do not respond to IFNα-2b therapy.1 It remains unclear which tumor-specific factors may affect treatment response or course after treatment.
Powered by Börsen-Handelssysteme